Share this video  

ESMO 2021 | Genomic landscape of late-stage gastric cancer treated with pembrolizumab

Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the results from a biomarker analysis examining the genomic landscape of late-stage gastric cancer and gastroesophageal junction adenocarcinoma in patients treated with pembrolizumab monotherapy or combined with chemotherapy. The Cancer Genome Atlas (TCGA) defines four categories of gastric cancers: microsatellite instability-high (MSI-H) tumours, Epstein–Barr virus (EBV)-positive tumors, chromosomally unstable tumors and genomically stable tumors. Dr Janjigian explains that their analysis revealed that MSI-H tumors were much rarer than suggested by the TCGA. Similarly, chromosomally unstable tumors are the most common subset in this population and there are no significant differences in tumor biology between patients from east and west Asia. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.